Trials / Terminated
TerminatedNCT03795350
Lung Deposition of TRIMBOW® pMDI in Healthy Volunteers, Asthmatic and COPD Patients
Open Label, Uncontrolled, Non-randomized, Single Dose, Scintigraphic Study to Investigate Lung Deposition of Inhaled 99mTc Radiolabelled TRIMBOW® pMDI in Healthy Volunteers, Asthmatic and COPD Patients
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Chiesi Farmaceutici S.p.A. · Industry
- Sex
- All
- Age
- 28 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate the lung deposition and distribution pattern of TRIMBOW using a Gamma-scintigraphic technique after inhalation of a single dose of 99mTc radiolabelled TRIMBOW administered via pMDI in healthy volunteers, asthmatic and COPD patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Beclometasone dipropionate Formoterol Fumarate Glycopyrronium Bromide | single inhalation of 99mTc radiolabelled TRIMBOW pMDI (4 puffs for a total dose of 400mcg BDP, 24mcg FF, 50 mcg GB) |
Timeline
- Start date
- 2019-01-14
- Primary completion
- 2020-04-03
- Completion
- 2020-04-03
- First posted
- 2019-01-07
- Last updated
- 2022-05-06
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03795350. Inclusion in this directory is not an endorsement.